Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC
NCT07085169
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Colo-rectal Cancer
Third-line and Beyond Therapy
TAS 102
Bevacizumab
Interventions
DRUG:
Trifluridine/tipiracil (TAS-102) plus bevacizumab
Sponsor
Ruijin Hospital